[go: up one dir, main page]

AR027179A1 - Formulas farmaceuticas liquidas de sabor enmascarado - Google Patents

Formulas farmaceuticas liquidas de sabor enmascarado

Info

Publication number
AR027179A1
AR027179A1 ARP000103477A ARP000103477A AR027179A1 AR 027179 A1 AR027179 A1 AR 027179A1 AR P000103477 A ARP000103477 A AR P000103477A AR P000103477 A ARP000103477 A AR P000103477A AR 027179 A1 AR027179 A1 AR 027179A1
Authority
AR
Argentina
Prior art keywords
eam
ester
liquid composition
liquidas
soluble
Prior art date
Application number
ARP000103477A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of AR027179A1 publication Critical patent/AR027179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion líquida para administracion oral que incluye un medicamento farmacéuticamente activo recubierto con una eficaz cantidad de agenteenmascarador del sabor de una mezcla de polímeros de (a) dimetilaminoetil metacrilato y un éster de ácido metacrílico neutro (MM/EAM) y (b) un éster decelulosa, en un medio acuoso, en la cual la proporcion en peso del pol{imero del éster de celulosa en relacion al MM/EAM es de aproximadamente 40:60 a 90:10preferentemente 60:40. La composicion líquida ut iliza una cobertura entérica invertida que es soluble en los pHs ácidos del estomago, generalmente de 1.0a 4.0, pero relativamente soluble en los pHs a neutro de la boca. Las coberturas permiten una rápida liberacion y absorcion de la droga, lo cual esgeneralmente deseable en el caso de formas de dosificacion líquidas.
ARP000103477A 1999-07-09 2000-07-07 Formulas farmaceuticas liquidas de sabor enmascarado AR027179A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14301999P 1999-07-09 1999-07-09

Publications (1)

Publication Number Publication Date
AR027179A1 true AR027179A1 (es) 2003-03-19

Family

ID=22502238

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103477A AR027179A1 (es) 1999-07-09 2000-07-07 Formulas farmaceuticas liquidas de sabor enmascarado

Country Status (25)

Country Link
US (2) US6482823B1 (es)
EP (1) EP1194153B1 (es)
JP (1) JP2003504335A (es)
KR (2) KR100675809B1 (es)
CN (1) CN1174740C (es)
AR (1) AR027179A1 (es)
AT (1) ATE265852T1 (es)
AU (1) AU773555B2 (es)
BR (1) BR0012326A (es)
CA (1) CA2377916C (es)
DE (1) DE60010464T2 (es)
DK (1) DK1194153T3 (es)
EE (1) EE05147B1 (es)
ES (1) ES2219360T3 (es)
HR (1) HRP20020119A2 (es)
HU (1) HUP0201765A3 (es)
IL (2) IL147510A0 (es)
MX (1) MXPA02000331A (es)
NO (1) NO20020086L (es)
NZ (1) NZ516486A (es)
PL (1) PL197812B1 (es)
PT (1) PT1194153E (es)
SK (1) SK322002A3 (es)
TR (1) TR200200710T2 (es)
WO (1) WO2001003698A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1276470T3 (da) * 2000-04-20 2007-06-18 Novartis Ag Smagskaskerende overtrækssammensætning
EP1372662A1 (en) 2001-03-05 2004-01-02 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
AU2003257093A1 (en) * 2002-08-02 2004-02-23 Eggs In The Pipeline, Llc. System for adding consumable enhancing additives to drinking water
US20080020096A1 (en) * 2003-08-01 2008-01-24 Blum Bradley J System for Adding Consumable Enhancing Additives to Drinking Water
DK1669090T3 (en) * 2003-09-12 2016-06-06 Ryukakusan Co Ltd Bitterness masking particulate gel
US7378015B2 (en) * 2003-12-18 2008-05-27 The Clorox Company Filtered water enhancements
US7713482B2 (en) 2003-12-18 2010-05-11 The Clorox Company Control scheme for enhanced filtered water systems
MXPA06011765A (es) * 2004-04-12 2006-12-15 Pfizer Prod Inc Farmacos de sabor enmascarado en multiparticulados que se rompen.
JP2006232789A (ja) * 2005-02-28 2006-09-07 Sawai Pharmaceutical Co Ltd 経口製剤用組成物及びその製造方法
US20060216355A1 (en) * 2005-03-28 2006-09-28 Donald Spector Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents
US7874489B2 (en) * 2005-06-20 2011-01-25 Authentiform Technologies, Llc Product authentication
US8458475B2 (en) * 2005-06-20 2013-06-04 Authentiform Technologies, L.L.C. Systems and methods for product authentication
US8247018B2 (en) * 2005-06-20 2012-08-21 Authentiform Technologies, Llc Methods for quality control
US7973022B2 (en) * 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
EP2091519B1 (en) 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
CN101618217B (zh) * 2009-07-27 2011-12-28 洛阳君山制药有限公司 一种安胃片的包衣方法
KR101636958B1 (ko) * 2009-09-11 2016-07-06 주식회사 대웅제약 우루소데옥시콜린산-합성하이드로탈사이트-유드라짓 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN102753196A (zh) * 2009-12-10 2012-10-24 莫诺索尔克斯有限公司 口服薄膜条内掩味的pH敏感性化合物
CA2784826A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
EP2915098A4 (en) 2012-10-30 2016-07-06 Certirx Corp PRODUCT, IMAGE, OR DOCUMENT AUTHENTICATION AND VERIFICATION AND OBJECT IDENTIFICATION
MX364381B (es) 2013-03-15 2019-04-25 Aprecia Pharmaceuticals LLC Forma de dosificacion de oxcarbazepina dispersable rapidamente.
ES2761407T3 (es) 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
WO2017161318A1 (en) 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
KR102088315B1 (ko) 2017-10-23 2020-03-13 주식회사 웅진릴리에뜨 장용성 캡슐의 이취 마스킹 방법 및 이를 이용한 이취의 마스킹 처리가 이루어진 장용성 캡슐
CA3087517A1 (en) * 2018-01-22 2019-07-25 Johnson & Johnson Consumer Inc. Perforated capsules
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
CN117503701A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 左氧氟沙星口服混悬液制剂及制剂制造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
US5065094A (en) 1990-08-07 1991-11-12 Seagate Technology, Inc. Two terminal magnetoresistive sensor having DC blocking capacitor
FR2665635A1 (fr) 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5599556A (en) 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
FR2694751B1 (fr) 1992-08-14 1994-11-25 Bouchara Sa Nouveaux dérivés sulfonamides, leurs procédés de préparation et les compositions en renfermant.
US5614222A (en) * 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof

Also Published As

Publication number Publication date
CA2377916A1 (en) 2001-01-18
CN1174740C (zh) 2004-11-10
SK322002A3 (en) 2003-02-04
IL147510A0 (en) 2002-08-14
KR20020031382A (ko) 2002-05-01
US6586012B2 (en) 2003-07-01
BR0012326A (pt) 2002-03-12
CA2377916C (en) 2008-03-11
PL197812B1 (pl) 2008-04-30
EP1194153A1 (en) 2002-04-10
KR100675809B1 (ko) 2007-02-01
EE200200012A (et) 2003-02-17
PL352761A1 (en) 2003-09-08
US6482823B1 (en) 2002-11-19
HUP0201765A3 (en) 2004-05-28
NO20020086D0 (no) 2002-01-08
HRP20020119A2 (en) 2003-12-31
DK1194153T3 (da) 2004-08-02
EP1194153B1 (en) 2004-05-06
MXPA02000331A (es) 2002-06-21
NO20020086L (no) 2002-03-05
CN1360504A (zh) 2002-07-24
DE60010464D1 (de) 2004-06-09
WO2001003698A1 (en) 2001-01-18
JP2003504335A (ja) 2003-02-04
KR20020029668A (ko) 2002-04-19
NZ516486A (en) 2003-10-31
ES2219360T3 (es) 2004-12-01
IL147510A (en) 2007-06-03
TR200200710T2 (tr) 2002-08-21
PT1194153E (pt) 2004-09-30
ATE265852T1 (de) 2004-05-15
AU5880200A (en) 2001-01-30
US20030064107A1 (en) 2003-04-03
DE60010464T2 (de) 2005-05-12
EE05147B1 (et) 2009-04-15
AU773555B2 (en) 2004-05-27
HUP0201765A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
AR027179A1 (es) Formulas farmaceuticas liquidas de sabor enmascarado
EA200200595A1 (ru) Лекарственная форма с высвобождением лекарства под действием гидрогеля
AR017984A1 (es) Proceso para formar una composicion farmaceutica de topiramato y composicion farmaceutica de topiramato
CR6458A (es) Composiciones de valdecoxib
CO4940409A1 (es) Tableta cubierta con pelicula para seguridad mejorada del tracto gastrointestinal superior
ATE30380T1 (de) Pharmazeutische formulierungen mit mehrfachen einheiten.
ES2180646T3 (es) Formulaciones liquidas orales de alendronato.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
CO4910118A1 (es) Procedimiento de preparacion de globulos con un contenido mayor = 50 % en peso de sustancia activa farmaceutica
AR032151A1 (es) Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada
PT916347E (pt) Solucoes farmaceuticas injectaveis contendo paracetamol e combinacoes de paracetamol com outras substancias activas
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR036096A1 (es) Formulacion farmaceutica de sabor enmascarado, un procedimiento para su preparacion y un procedimiento de enmascaramiento del sabor de productos farmaceuticos
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
AR003921A1 (es) Combinacion activa farmaceutica
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
DK0693926T3 (da) Ny farmaceutisk sammensætning til fremstilling af et stabilt pulver indeholdende en kombination af acetylsalicylsyre og metoclopramid som aktiv bestanddel.
CO5150233A1 (es) Formulacion de liberacion controlada para administrar un inhibidor de pde4
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
DK1300143T3 (da) Plaster som indeholder 4-biphenyleddikesyre
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
ES2129563T3 (es) Empleo de una combinacion de un inhibidor de la enzima convertidora de angiotensina y un antagonista del calcio para el tratamiento de una proteinuria.
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов

Legal Events

Date Code Title Description
FB Suspension of granting procedure